Survodutide is a dual glucagon/glucagon-like peptide 1 (GLP1) receptor agonist. Survodutide has demonstrated blood sugar lowering efficacy in a Phase II trial for the treatment of patients with type 2 diabetes and obesity and was associated with clinically meaningful weight loss[1]. Survodutide is also being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)[2].
苏州默迪夫生物科技有限公司
联系商家时请提及chemicalbook，有助于交易顺利完成！
Motif